Clinical trials: Restless Legs Syndrome
Restless Legs Syndrome
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the long-term safety and efficacy of XP13512 (Gabapentin Enacarbil) taken once daily for the treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00333359
- Testing
- XP13512 (GEn)
- Volunteers
- 581 people
- Sponsor
- XenoPort, Inc.
Apnea, Restless Legs Syndrome
Validation Study for an Unobtrusive Online Sleep Measurement System
The purpose of the study is to determine the precision of an unobtrusive sleep measurement system. The system measures a force sensor signal under the mattress and analyzes sleep quality.
- Conditions
- Apnea, Restless Legs Syndrome, Sleep Fragmentation
- Trial name
- NCT01633151
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Beddit.com Ltd
Restless Legs Syndrome (RLS)
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
To evaluate the safety, efficacy and pharmacokinetics of gabapentin enacarbil in moderate to severe primary RLS patients with moderate renal impairment and to confirm dosage and administration in such population.
- Trial name
- NCT01981941
- Testing
- Gabapentin enacarbil
- Where
- 5 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Astellas Pharma Inc
Restless Legs Syndrome
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system.
- Trial name
- NCT01495793
- Testing
- Rotigotine
- Where
- 12 sites in United States
- Volunteers
- 42 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Restless Legs Syndrome
The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome
The purpose of this study is to assess the efficacy and tolerability of single doses of aplindore compared to placebo in RLS. Patients will be required to spend 5-8 nights in a sleep laboratory.
- Trial name
- NCT00626418
- Testing
- Aplindore
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Ligand Pharmaceuticals
Restless Legs Syndrome
Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance
The purpose of this study is to assess the efficacy and safety of pregabalin and pramipexole versus placebo in the treatment of restless legs syndrome and associated sleep disturbance.
- Trial name
- NCT00991276
- Testing
- pregabalin, pramipexole
- Where
- 41 sites in United States
- Volunteers
- 85 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Restless Legs Syndrome
Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome
The objective of the study was to generate the data necessary to determine the gabapentin exposure produced by 4 dose levels of GEn (600 mg, 1200 mg, 1800 mg, and 2400 mg) or placebo, and the corresponding relief of symptoms in…
- Trial name
- XP081 (NCT01332305)
- Testing
- GEn (XP13512/GSK1838262)
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
The objective of this study is to evaluate the efficacy and safety of ASP8825 (gabapentin enacarbil) for long-term treatment of restless legs syndrome patients.
- Trial name
- NCT02658188
- Testing
- ASP8825
- Where
- 10 sites in Japan
- Volunteers
- 182 people
- Sponsor
- Astellas Pharma Inc
Idiopathic Restless Legs Syndrome
Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)
The objective of this study is to evaluate the clinical efficacy and safety of SPM962 in patients with restless legs syndrome (RLS) with once-daily repeated doses of 4.5mg and 6.75mg during a 13-week dose-titration and…
- Trial name
- NCT01084551
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Idiopathic Restless Legs Syndrome
A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients
The primary objective of this study is to investigate efficacy and safety of SPM 962 in Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group comparative study following once-daily multiple…
- Trial name
- NCT00666965
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 230 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Restless Legs Syndrome (RLS)
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
The objective of this study was to assess the efficacy of once-daily oral administration of gabapentin enacarbil versus placebo, based on the change in International Restless Legs Syndrome Rating Scale (IRLS) score in…
- Trial name
- NCT03053427
- Testing
- Gabapentin enacarbil
- Where
- 46 sites in Japan
- Volunteers
- 375 people
- Sponsor
- Astellas Pharma Inc
Restless Legs Syndrome
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
The purpose of the study is to show that Rotigotine improves Restless Legs Syndrome (RLS) symptoms in subjects with moderate to severe RLS during both day and evening.
- Trial name
- RESTORE (NCT01569464)
- Testing
- Rotigotine
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- UCB Pharma
Restless Legs Syndrome
Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)
The purpose of this study was to evaluate the efficacy and safety of different doses of pramipexole (Sifrol) on subjective and objective symptoms of idiopathic Restless Legs Syndrome (RLS) and also to determine the optimal dose…
- Trial name
- NCT00239486
- Testing
- Pramipexole
- Where
- Finland
- Volunteers
- 109 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome
This study was designed to evaluate the safety, pharmacokinetic profile and efficacy in Restless Legs Syndrome patients.
- Trial name
- NCT00530790
- Testing
- ropinirole controlled release (CR)-RLS
- Where
- 11 sites in Japan
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
Response to an Investigational Device in Patients With Restless Legs Syndrome
This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.
- Trial name
- NCT06866132
- Testing
- Investigational Noninvasive Neuromodulation Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noctrix Health, Inc.
Sleep Disorder, Restless Legs Syndrome
Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) in patients with Restless Legs Syndrome.
- Trial name
- NCT00199446
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Kyowa Kirin, Inc.
Restless Legs Syndrome
Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life
In this German non-interventional observational study 1980 patients diagnosed with Restless Legs Syndrome (RLS) will be investigated by 990 General Practitioners across all federal states in Germany.
- Trial name
- NCT00539461
- Where
- 317 sites in Germany
- Volunteers
- 2,023 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
This trial is a 6-week, double-blind, randomized, active and placebo-controlled parallel-group study with a primary objective of comparison of starting doses of pramipexole fixed-dose (0.25 mg daily) and pramipexole titrated-dose…
- Trial name
- NCT00375284
- Testing
- Pramipexole
- Where
- 52 sites in United States
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim
Restless Leg Syndrome (RLS)
Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment
The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS).
- Trial name
- RLS-DRD2gene (NCT06726785)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HBC Immunology Inc